Ratio and Novartis Partner for Cancer Treatment

Ratio Therapeutics has entered a major collaboration with Novartis Pharma AG to develop a next-generation Somatostatin Receptor 2 (SSTR2)-targeting radiopharmaceutical for cancer treatment. Under the agreement, Ratio will receive upfront and milestone payments potentially reaching $745 million, along with tiered royalties. The companies will work together on preclinical research, with Novartis assuming responsibility for further development, manufacturing, and commercialization efforts.

This collaboration combines Ratio's expertise in radioligand therapy discovery with Novartis' capabilities in advancing cancer treatments, aiming to deliver a potent new therapeutic option for patients with SSTR2-expressing tumors.